Loading clinical trials...
Loading clinical trials...
The primary objective of this study will explore whether circulating acyl-ghrelin (AG) and unacylated-ghrelin (UAG) are reduced in neurodegenerative disease associated with cognitive impairment. It will focus on validating pilot data generated following the analysis of Parkinson's disease (PD), Parkinson's disease dementia (PDD) and healthy cohorts (IRAS project ID: 250933). In addition to the advantages of study replication we will extend the analysis to include two further patient groups that are associated with cognitive impairments, namely, Alzheimer's dementia (AD) and dementia with Lewy bodies (DLB). This study will increase confidence in the replication of our findings. This will be a cross-sectional study using peripheral venous blood.
Age
60 - No limit years
Sex
ALL
Healthy Volunteers
Yes
Swansea University
Swansea, United Kingdom
Start Date
August 15, 2022
Primary Completion Date
September 1, 2024
Completion Date
September 1, 2024
Last Updated
October 26, 2023
100
ESTIMATED participants
Venous blood collection
DIAGNOSTIC_TEST
Lead Sponsor
Swansea University
Collaborators
NCT04246437
NCT05508789
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions